Indication for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).pharmacodynamics estradiol, the principal intracellular human estrogen, is substantially more active than its metabolites, estrone and estriol, at the cellular level.mechanism of action estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. when the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger rna. the mrna interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stim